Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimising systemic activity (vol 6, pg 137, 2013)

被引：0
|
作者：
Prantera, C. [1 ]
Marconi, Stefano [1 ]
机构：
[1] Chiesi Farmaceutici SpA, Parma, Italy
来源：
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY | 2013年 / 6卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：420 / 420
页数：1
相关论文
共 50 条
  • [21] TNFAIP6 is a disease activity marker in inflammatory bowel disease
    Yu, Q.
    Zhang, S.
    Wang, H.
    Ben-Horin, S.
    Mao, R.
    Zhang, Y.
    Feng, T.
    Li, L.
    Chen, B.
    He, Y.
    Chen, M.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S477 - S477
  • [22] The 2023 Impact of Inflammatory Bowel Disease in Canada: The Influence of Sex and Gender on Canadians Living With Inflammatory Bowel Disease (vol 6, pg s55, 2023)
    Targownik, Laura E.
    JOURNAL OF THE CANADIAN ASSOCIATION OF GASTROENTEROLOGY, 2024, 7 (03) : 277 - 277
  • [23] Antipsychotics in the treatment of schizophrenia (vol 17, pg 6, 2013)
    不详
    PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2013, 17 (04) : 20 - 20
  • [24] Assessment of respiration activity and ecotoxicity of composts containing biopolymers (vol 89, pg 137, 2013)
    Kopec, Michal
    Gondek, Krzysztof
    Baran, Agnieszka
    ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY, 2014, 104 : 429 - 429
  • [25] Principles of topical versus systemic corticoid treatment in inflammatory bowel disease
    Mollmann, HW
    Barth, J
    Hochhaus, G
    Mollmann, AC
    Derendorf, H
    Tromm, A
    GLUCOCORTICOID THERAPY IN CHRONIC INFLAMMATORY BOWEL DISEASE: FROM BASIC PRINCIPLES TO RATIONAL THERAPY, 1996, 73B : 42 - 60
  • [26] Systemic redox status associates with disease activity and clinical phenotypes in Inflammatory Bowel Disease
    Geertsema, S.
    Bourgonje, A. R.
    Gacesa, R.
    Fagundes, R. R.
    Spekhorst, L. M.
    Hu, S.
    Kannan, A. K.
    Ruane, D.
    de Jong, S.
    Jansen, B. H.
    Bulthuis, M. L. C.
    Reinders-Luinge, M.
    Weersma, R. K.
    van Goor, H.
    Dijkstra, G.
    Faber, K. N.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I577 - +
  • [27] SYSTEMIC REDOX STATUS ASSOCIATES WITH DISEASE ACTIVITY AND CLINICAL PHENOTYPES IN INFLAMMATORY BOWEL DISEASE
    Geertsema, Sem
    Bourgonje, Arno R.
    Gacesa, Ranko
    Fagundes, Raphael R.
    Spekhorst, Lieke M.
    Hu, Shixian
    Kannan, Arun K.
    Ruane, Darren
    de Jong, Sofie
    Jansen, Dianne
    Bulthuis, Marian
    Reinders-Luinge, Marjan
    Weersma, Rinse K.
    Van Goor, Harry
    Dijkstra, Gerard
    Faber, Klaas Nico
    GASTROENTEROLOGY, 2024, 166 (05) : S522 - S523
  • [28] Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine
    Su, CY
    Lichtenstein, GR
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2004, 33 (02) : 209 - +
  • [29] Treatment approaches for irritable bowel syndrome (vol 7, pg 90, 2007)
    不详
    REVIEWS IN GASTROENTEROLOGICAL DISORDERS, 2007, 7 (03) : 166 - 166
  • [30] TNFAIP6 is a potential biomarker of disease activity in inflammatory bowel disease
    Yu, Qiao
    Zhang, Shenghong
    Wang, Huiling
    Zhang, Yingfan
    Feng, Ting
    Chen, Baili
    He, Yao
    Zeng, Zhirong
    Chen, Minhu
    BIOMARKERS IN MEDICINE, 2016, 10 (05) : 473 - 483
12345